2,4,6-Trimethyl-N-((3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)methyl)-N-((5-(trifluoromethyl)furan-2-yl)methyl)benzenesulfonamide 2,4,6-三甲基-N-((3'-(甲基磺酰基)-[1,1'-联苯]-4-基)甲基)-N-((5-(三氟甲基)呋喃-2-基)甲基)苯磺酰胺

CAS 1221277-90-2 MFCD321277902

化学结构图

1221277-90-2
SMILES:

别名和识别编码

Chemical Name Translation2,4,6-三甲基-N-((3'-(甲基磺酰基)-[1,1'-联苯]-4-基)甲基)-N-((5-(三氟甲基)呋喃-2-基)甲基)苯磺酰胺
Chemical Name2,4,6-Trimethyl-N-((3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)methyl)-N-((5-(trifluoromethyl)furan-2-yl)methyl)benzenesulfonamide
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

相关文献及参考

  • [2]. Griffett K, et al. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun. 2016 Oct 21;479(3):424-428.
  • [1]. Zuercher WJ, et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6.
  • [1]. Zuercher WJ, et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6.
  • [2]. Griffett K, et al. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun. 2016 Oct 21;479(3):424-428.

系列性分类

  1. Medical Research Areas
  2. Metabolism
  3. LXR  (肝X受体)

相关产品推荐